← UNITED THERAPEUTICS Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.6b |
$1.7b
+7.91%
|
$1.6b
-5.65%
|
$1.4b
-11.00%
|
$1.5b
+2.38%
|
$1.7b
+13.63%
|
$1.9b
+14.88%
|
$2.3b
+20.20%
|
$2.9b
+23.63%
|
$3.2b
+10.61%
|
$3.2b
-0.89%
|
|
| Cost of Revenue | $72.7m |
$105.7m
+45.39%
|
$198.7m
+87.98%
|
$117.6m
-40.82%
|
$108.1m
-8.08%
|
$122.5m
+13.32%
|
$151.6m
+23.76%
|
$257.5m
+69.85%
|
$309.7m
+20.27%
|
$384.4m
+24.12%
|
$437.2m
+13.74%
|
|
| Gross Profit | $1.5b |
$1.6b
+6.13%
|
$1.4b
-11.76%
|
$1.3b
-6.85%
|
$1.4b
+3.31%
|
$1.6b
+13.66%
|
$1.8b
+14.18%
|
$2.1b
+15.99%
|
$2.6b
+24.04%
|
$2.8b
+8.98%
|
$2.7b
-2.89%
|
|
| Research and Development Expense | $147.6m | $264.6m | $357.9m | $1.2b | $357.7m | $540.1m | $322.9m | $408.0m | $481.0m | $550.0m | $551.5m | |
| Selling, General and Administrative Expense | $316.8m | $330.1m | $265.8m | $336.2m | $423.9m | $467.0m | $482.1m | $477.1m | $709.7m | $755.8m | $761.0m | |
| Amortization of Intangible Assets | $600k | $500k | $100k | $200k | $200k | $100k | $100k | $300k | $900k | $900k | — | |
| Operating Lease, Expense | — | — | — | — | $3.5m | $3.6m | $4.8m | — | — | — | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $1.1b |
$814.9m
-23.25%
|
$805.4m
-1.17%
|
($187.6m)
-123.29%
|
$593.6m
+416.42%
|
$555.9m
-6.35%
|
$979.7m
+76.24%
|
$1.2b
+20.95%
|
$1.4b
+16.21%
|
$1.5b
+8.39%
|
$1.4b
-5.88%
|
|
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | — | $0 | — | $1.8m | $0 | $600k | — | |
| Other Nonoperating Income (Expense) | $2.4m | $13.2m | ($7.7m) | $22.6m | $49.3m | $42.2m | ($40.2m) | ($14.0m) | $5.8m | $48.9m | — | |
| Interest Expense (non-operating) | $3.9m | $9.0m | $13.9m | $44.2m | $23.5m | $18.6m | $32.4m | $59.3m | $42.9m | $19.5m | $12.0m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $1.7b | $1.6b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $1.1b | $769.5m | $758.9m | ($165.0m) | $638.9m | $593.9m | $950.6m | $1.3b | $1.5b | $1.7b | $1.6b | |
| Current Income Tax Expense (Benefit) | $336.0m | $285.2m | $154.0m | $72.5m | $134.6m | $136.9m | $274.1m | $353.9m | $408.0m | $281.5m | $262.1m | |
| Income Tax Expense (Benefit) | $346.5m | $351.6m | $169.7m | ($60.5m) | $124.1m | $118.1m | $223.3m | $289.5m | $343.9m | $379.2m | $262.1m | |
| Net Income (Loss) Attributable to Parent | $713.7m |
$417.9m
-41.45%
|
$589.2m
+40.99%
|
($104.5m)
-117.74%
|
$514.8m
+592.63%
|
$475.8m
-7.58%
|
$727.3m
+52.86%
|
$984.8m
+35.40%
|
$1.2b
+21.35%
|
$1.3b
+11.68%
|
$1.3b
-1.78%
|
|
| Earnings Per Share, Basic | $16.29 | $9.50 | $13.54 | ($2.39) | $11.65 | $10.60 | $15.98 | $21.04 | $26.44 | $30.13 | $30.23 | |
| Earnings Per Share, Diluted | $15.25 | $9.31 | $13.39 | ($2.39) | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 | $27.91 | |
| Weighted Average Number of Shares Outstanding, Basic | 43.8m | 44.0m | 43.5m | 43.8m | 44.2m | 44.9m | 45.5m | 46.8m | 45.2m | 44.3m | 43.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | 46.8m | 44.9m | 44.0m | 43.8m | 44.6m | 47.3m | 48.5m | 49.7m | 48.5m | 47.9m | 46.9m | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | — | — | $5.4m | — | — | — | — | — | — | — | — | |
| Costs and Expenses | $537.1m | $910.4m | $822.4m | $1.6b | $889.7m | $1.1b | $956.6m | $1.1b | $1.5b | $1.7b | — | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | $2.3m | $1.7m | $0 | $0 | — | — | |
| Goodwill, Impairment Loss | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.